•
Sep 30, 2020

Paysign Q3 2020 Earnings Report

Reported third quarter 2020 financial results, noting the pandemic's continued impact on the business due to its adverse effect on clients in the pharma and plasma industries.

Key Takeaways

Paysign reported its third quarter 2020 financial results, acknowledging the ongoing impact of the pandemic on its business, particularly affecting clients in the pharma and plasma industries. The company remains optimistic about recovery and targets a return to year-over-year growth, contingent on the pandemic's effects. Paysign is well-capitalized and anticipates an upturn in the fourth quarter from new client programs.

The pandemic continues to significantly impact Paysign's business, particularly affecting clients in the pharma and plasma industries.

Paysign remains cautiously optimistic about the recovery of its clients and aims to return to year-over-year growth, depending on the pandemic's effects.

The company is well-capitalized and prepared to withstand ongoing pandemic-related impacts.

Paysign anticipates an additional upturn in the fourth quarter due to the onboarding of new client programs.

Total Revenue
-$153K
Previous year: $9.01M
-101.7%
EPS
-$0.14
Previous year: $0.06
-333.3%
Gross Profit
-$3.43M
Previous year: $5.37M
-164.0%
Cash and Equivalents
$55.5M
Previous year: $41.2M
+34.7%
Free Cash Flow
$8.27M
Previous year: -$7.51M
-210.2%
Total Assets
$71.1M
Previous year: $47.6M
+49.3%

Paysign

Paysign

Forward Guidance

Paysign anticipates an upturn in the fourth quarter resulting from new client programs.